Optimizing Nourishment in the NICU
The Connecticut Children’s Neonatal Intensive Care Unit at the UConn John Dempsey Hospital is offering a high-tech tool for moms to ensure their infants get the most out of breast milk and formula feeding.
Optimizing Nourishment in the NICU
The Connecticut Children’s Neonatal Intensive Care Unit at the UConn John Dempsey Hospital is offering a high-tech tool for moms to ensure their infants get the most out of breast milk and formula feeding.
Ride Health and COVID-19 Prevention Trials Network (CoVPN) Partner to Provide Transportation for Vaccine Trial Participants
Fred Hutchinson-led ‘harmonizer’ network for Operation Warp Speed vaccines leverages company’s COVID-equipped transportation network for five vaccines in Phase III clinical trials
Ride Health and ACTIV-2 Partner to Provide Transportation for Nationwide COVID-19 Therapeutic Study
NIH-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2) study leveraging company’s COVID-19 equipped transportation network across dozens of sites nationwide
Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita
~ VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion ~
~ VALO Study Achieves Primary Endpoint in Phase 2 Open-Label Portion ~
~ Palvella Plans to Share Results with the U.S. Food and Drug Administration in the First Quarter of 2021 ~
Oncora Medical to power Mass General’s Pediatric Proton/Photon Consortium Registry to fight pediatric cancer with data
TiE Boston recognizes Purnanand Sarma, Ph.D. President & CEO of Immunome, as 2020 Lifetime Achievement Awardee
Dr. Sarma to be honored at the 2020 TiE Boston Gala, Keynote Fireside Chat with Kiran Mazumdar-Shaw, CMD of Biocon
ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline
Envara Health Named Winner of Rabobank’s FoodBytes! Pitch 2020 Competition
Advanced Nutrition Company Recognized in Food Tech Category with Award for Innovation in Clinical Nutrition
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with
Major Depressive Disorder